SS-31 50mg Elamipretide | Research Peptide UK

For research use only. Not for human consumption.

SS-31 (Elamipretide / MTP-131 / Bendavia) — 50mg | ≥99% Purity | COA Verified | UK Dispatch

SS-31, also known as Elamipretide (development codes MTP-131, Bendavia, SBT-272), is a synthetic aromatic-cationic tetrapeptide specifically designed to selectively target and accumulate within the inner mitochondrial membrane. First characterised by Szeto and Schiller, SS-31 is among the most clinically investigated mitochondria-targeted peptides, with completed Phase I–III trials in Barth syndrome, heart failure, primary mitochondrial myopathy, renal artery stenosis, and age-related macular degeneration. It received FDA approval in September 2025 under the brand name Forzinity for the treatment of Barth syndrome — making it one of the few research peptides to achieve approved medicine status, underscoring the depth of its clinical evidence base.

Mechanism of Action in Research SS-31 exerts its effects primarily through direct binding to cardiolipin — a unique phospholipid found exclusively in the inner mitochondrial membrane, essential for electron transport chain function and mitochondrial membrane integrity. By stabilising cardiolipin, SS-31 is studied for its ability to:

• Prevent cytochrome c peroxidase activity and reduce mitochondrial ROS generation
• Restore electron transport chain efficiency and ATP synthesis capacity
• Maintain inner mitochondrial membrane potential under conditions of oxidative stress
• Protect against mitochondrial swelling and membrane permeabilisation associated with cell death pathways

Key Research Areas SS-31 is one of the most broadly studied mitochondria-targeted peptides in preclinical research, with significant interest across multiple disciplines:

• Mitochondrial dysfunction & cardiolipin protection — the defining mechanism: SS-31 selectively binds and stabilises cardiolipin in the inner mitochondrial membrane, preserving electron transport chain architecture under oxidative stress
• Cardiovascular research — studied in heart failure models; preclinical data demonstrate improvements in left ventricular function, mitochondrial energetics, and cardiac output in advanced heart failure animal models
• Age-related muscle decline & sarcopenia — in aged mouse models, SS-31 reversed age-related decline in mitochondrial ATP production, restored redox homeostasis, and significantly improved skeletal muscle mass, fatigue resistance, and treadmill endurance
• Neurodegenerative disease models — studied in models of Alzheimer's, Parkinson's, and LPS-induced neuroinflammation; shown to reduce mitochondrial dysfunction, oxidative stress, neural apoptosis, and dendritic spine loss in the hippocampus
• Renal protection — clinical pilot data demonstrate attenuated post-procedural hypoxia and improved renal blood flow when used adjunctively; preclinical models show protection in ischaemia-reperfusion injury and diabetic nephropathy
• Metabolic & inflammatory pathways — modulation of SIRT1, NF-κB, and oxidative stress markers in type 2 diabetes models; increased glutathione redox ratio and reversal of cysteine S-glutathionylation in aged skeletal muscle
• Mitochondrial myopathy & Barth syndrome — the compound with the longest clinical track record in primary mitochondrial disease; FDA approved September 2025 for Barth syndrome
• Age-related macular degeneration — Phase 1 clinical trial demonstrated safety and tolerability via subcutaneous administration in AMD patients with high-risk drusen

Product Specifications

• CAS Number: 736992-21-5
• Sequence: D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH₂ (D-Arg-Dmt-Lys-Phe-NH₂)
• Other Names: Elamipretide, MTP-131, Bendavia, SBT-272, Szeto-Schiller-31, Forzinity (brand)
• Molecular Formula: C₃₂H₄₉N₉O₅
• Molecular Weight: 639.8 g/mol
• PubChem CID: 11764719
• Amino Acids: 4 (tetrapeptide)
• Quantity: 50mg per vial
• Purity: ≥99% (HPLC verified)
• Solubility: Water soluble; highly cell-permeable, rapidly accumulates in mitochondria independent of membrane potential
• Storage: Refrigerate at 2–8°C once mixed. Do not freeze reconstituted solution. Protect from light and UV exposure. Avoid repeated freeze-thaw cycles. Lyophilised (unmixed) stable below −18°C long-term.
• Dispatch: Fast UK dispatch. Orders placed before 2pm dispatched same working day.

COA Available: Every batch independently third-party tested. Certificate of Analysis available on our Lab Reports page before ordering.

All products sold by Ultra Peptides are strictly for laboratory and in-vitro research purposes only. Not intended for human or veterinary use outside of approved clinical or research contexts. Not approved by the MHRA for any cosmetic, therapeutic, or general medical application in the UK. By purchasing this product you confirm your intended use is for legitimate scientific research conducted in a controlled laboratory setting.